Stocks in Play: BioVaxys Technology Corp
I'm PortAI, I can summarize articles.
10:21 AM EST - BioVaxys Technology Corp : Announces positive preliminary results from the PESCO study, an investigator-initiated, open-label, non-randomized phase 1B/2 trial to evaluate the safety and efficacy of combination of BioVaxys' MVP-S with pembrolizumab and cyclophosphamide in patients with recurrent epithelial ovarian cancer. BioVaxys Technology Corp shares C.BIOV are trading off $0.01 at $0.25.Full Press Release:
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Baystreet The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments